Increased levels of FNDC5 are associated with a reduced risk of breast cancer, and FNDC5 can be used for differential diagnosis and prognosis of breast cancer (Zhang et al., 2018).The serum irisin level in renal cancer patients was significantly higher than that in healthy controls suggesting that serum irisin could be used as a biomarker for the diagnosis of renal cancer (Thomas et al., 2017). Here, FNDC5 is linked to breast carcinoma.